(KROS) Keros Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KROS) Keros Therapeutics, Inc. Complete Analysis Pack
Keros Therapeutics’ Business Model, Unpacked
Unlock the full strategic blueprint behind Keros Therapeutics, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, partners with key stakeholders, and navigates the biotech landscape. Ideal for investors, analysts, and strategists, the full version delivers deeper insight and actionable detail.
Partnerships
Contract research organizations
Keros Therapeutics, Inc. uses contract research organizations to run outsourced clinical operations for Phase 1 and later studies, including KER-050, KER-047, and KER-012. This keeps the Company from building a large internal trial network and helps it scale development across multiple programs at once.
Contract development and manufacturing organizations
Keros Therapeutics, Inc. uses contract development and manufacturing organizations to supply protein therapeutics and small molecules, and to run GMP production, scale-up, and batch release. These partners also carry key CMC work during clinical development, which helps Keros keep its pipeline moving without building all manufacturing in-house.
Academic medical centers
Academic medical centers help Keros Therapeutics, Inc. run patient screening, enrollment, and protocol execution in 3 core areas: hematology, bone disease, and pulmonary hypertension. In 2025, Keros Therapeutics still had no product revenue, so these centers are key for generating translational clinical data that can support later-stage readouts and capital use.
Regulatory agencies
Regulatory agencies are a core partner for Keros Therapeutics, Inc., with the U.S. FDA guiding IND filings, safety review, and trial oversight. That alignment shapes study design, endpoints, and the approval path in the U.S. and in other markets, where similar agency reviews are needed for global development.
- FDA shapes IND and safety plans.
- Global trials need local approvals.
- Regulatory fit affects approval speed.
Investigators and key opinion leaders
Keros Therapeutics, Inc. relies on hematology, musculoskeletal, and pulmonary hypertension key opinion leaders to shape trial design, endpoint choice, and patient selection for rare-disease programs. That matters in markets like pulmonary arterial hypertension, which affects about 15 to 50 people per million adults, where the wrong endpoints can slow approval and burn cash fast.
- Guides endpoint selection
- Improves patient matching
- De-risks rare-disease trials
Keros’ Rare-Disease Pipeline Runs on Key External Partners
Keros Therapeutics, Inc. depends on CROs, CDMOs, academic medical centers, regulators, and key opinion leaders to run its rare-disease pipeline, from trial design to GMP supply and patient enrollment. In 2025, the Company still had no product revenue, so these partners were central to advancing KER-050, KER-047, and KER-012 without heavy in-house buildout.
| Partner | Role | Key data |
|---|---|---|
| CROs | Clinical ops | Phase 1 and later trials |
| CDMOs | Manufacturing | GMP, scale-up, release |
| Academic centers | Enrollment | Hematology, bone, PH |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Keros Therapeutics, mapping its biotech pipeline, partnerships, and value creation strategy.
Customizable Excel Spreadsheet
Quickly maps Keros Therapeutics’ business model to reveal key pain points and opportunities at a glance.
Reference Sources
Provides a concise source trail for Keros Therapeutics, helping validate claims, speed due diligence, and support confident decisions.
Activities
KER-050 clinical development
Keros Therapeutics, Inc. is advancing 1 flagship program, KER-050, for cytopenias, with a focus on 2 key blood-count deficits: anemia and thrombocytopenia in 2 disease settings, myelodysplastic syndromes and myelofibrosis.
KER-047 Phase 1 studies
KER-047 is Keros Therapeutics, Inc.'s small-molecule Phase 1 asset for anemia, and early human readouts are used to set dose and safety limits before later studies. In Phase 1, the key activity is generating first-in-human data on tolerability, pharmacokinetics, and pharmacodynamics to guide the next trial design.
KER-012 Phase 1 studies
KER-012 is Keros Therapeutics, Inc.'s small-molecule Phase 1 program, being tested in bone degeneration diseases and pulmonary arterial hypertension. By moving into two non-hematology uses, it broadens Company Name’s pipeline beyond its core blood-disorder focus and raises the value of its early-stage R&D engine.
Preclinical research and translational biology
Keros Therapeutics, Inc. must keep pushing discovery and mechanism work because preclinical biology is what turns BMP-pathway science into new indications, biomarker picks, and hard go or no-go calls. In 2025, the company kept that pipeline-led model focused on translational data that can de-risk later clinical bets.
- Find new uses
- Pick response biomarkers
- Stop weak programs early
Regulatory and CMC management
Keros Therapeutics, Inc. runs regulatory and CMC management across 2 clinical-stage assets, so IND maintenance, safety reporting, and trial submissions stay active every quarter. CMC work keeps drug substance and drug product quality locked in, and it is a must-have function for both programs.
- 2 clinical assets need ongoing IND upkeep
- Safety reports and trial filings never stop
- CMC protects drug quality and consistency
Keros Advances 3 Pipeline Tracks With 2 Clinical-Stage Assets
Keros Therapeutics, Inc. kept Key Activities centered on 3 pipeline tracks in 2025: KER-050 clinical development, KER-047 and KER-012 Phase 1 work, plus preclinical discovery to find new BMP-pathway uses and biomarkers. Ongoing IND, safety, and CMC work supported 2 clinical-stage assets.
| Activity | 2025 focus |
|---|---|
| Clinical | 2 assets |
| Discovery | New uses, biomarkers |
| Regulatory | IND, safety, CMC |
Preview Before You Purchase
Business Model Canvas
This Keros Therapeutics, Inc. Business Model Canvas preview is the exact same document you’ll receive after purchase. It’s not a sample or placeholder—what you see here is a direct preview of the final file. Once you buy, you’ll get full access to this same professionally formatted document, ready to use.
Resources
Three clinical-stage assets
Keros Therapeutics, Inc. has 3 clinical-stage assets: KER-050, KER-047, and KER-012. This pipeline is its core strategic resource, aimed at hematological and musculoskeletal diseases and still the main driver of R&D value.
Proprietary drug development know-how
Keros Therapeutics, Inc. relies on proprietary drug development know-how in protein therapeutics and small molecules, a skill set that shapes target selection and clinical design. As a clinical-stage biotech with no approved products in FY2025, this expertise is one of its hardest-to-copy assets and helps it move multiple pipeline programs forward with tighter scientific focus.
Clinical and biomarker data
Keros Therapeutics, Inc. treats Phase 1 and ongoing biomarker data as core assets: they help set dose, track safety, and test proof of mechanism for programs like KER-065. In 2025, Keros used these readouts to guide pipeline decisions and support future partnering and financing, where clean human data can matter as much as cash.
Intellectual property portfolio
Keros Therapeutics, Inc. depends on its intellectual property portfolio to protect its pipeline, since patents and related rights are what keep a biotech’s value from being copied once the science is public. That IP is central to defensibility and can extend value well beyond the research phase, especially before any approved product revenue exists.
- Protects pipeline claims
- Extends value past R&D
- Drives biotech defensibility
Lexington, Massachusetts headquarters
Keros Therapeutics, Inc. runs its principal operations from Lexington, Massachusetts, where leadership and core teams sit. That single hub anchors coordination across research and development, regulatory, and corporate work, keeping decisions close to the science.
For a biotech like Keros, this HQ is a key resource because it concentrates oversight in one place.
- Lexington HQ hosts leadership
- Supports R&D and regulatory work
- Centralizes corporate coordination
Keros’ 3-Asset Pipeline Drives FY2025 Value
Keros Therapeutics, Inc.'s key resources are its 3 clinical-stage assets, its IP, and its Lexington, Massachusetts base. In FY2025, with no approved products, these assets were the main source of pipeline value and deal leverage.
| Resource | FY2025 data | Role |
|---|---|---|
| Pipeline | 3 assets | Core value driver |
| HQ | Lexington, MA | Central control |
| Status | No approved products | R&D focus |
Value Propositions
Options for MDS cytopenias
KER-050 targets anemia and thrombocytopenia in myelodysplastic syndromes, where about 90% of patients develop anemia and up to half develop thrombocytopenia. With few durable treatment choices, Keros Therapeutics, Inc. is aiming at a clear unmet need in a disease that affects roughly 60,000 people in the U.S. each year.
Options for myelofibrosis cytopenias
KER-050 targets myelofibrosis cytopenias, a major burden in a disease where anemia affects more than half of patients and thrombocytopenia is common. The program is designed to improve blood cell counts and reduce transfusion need, addressing a clear unmet need in a market where myelofibrosis prevalence is roughly 1 to 1.5 per 100,000 people annually.
Phase 1 anemia therapy
Keros Therapeutics, Inc.'s Phase 1 anemia therapy, KER-047, adds a second mechanism to the pipeline, giving the Company another path beyond its existing blood-disorder program. As a clinical-stage small molecule, it could widen use across anemia and other hematology settings if early safety and activity hold up in 2026 data readouts.
Bone disease treatment candidates
KER-012 targets bone fragility in osteoporosis and osteogenesis imperfecta, two high-need areas with few approved options. Osteoporosis affects about 500 million people worldwide and causes roughly 9 million fractures each year, while osteogenesis imperfecta occurs in about 1 in 15,000 to 20,000 births.
- Targets severe bone fragility
- Addresses limited treatment choice
- Built for high unmet musculoskeletal need
Rare-disease innovation platform
Keros Therapeutics, Inc. is built around one rare-disease engine: a pipeline of 3 clinical assets across hematological and musculoskeletal disorders with few approved treatments. That concentration can turn one biology platform into multiple shots at value creation, while the unmet-need focus supports premium pricing if trials land well.
- 3 clinical assets
- Multiple rare indications
- One shared research platform
- Focus on low-treatment areas
Keros Targets Rare-Disease Gaps With First-in-Class Pipeline
Keros Therapeutics, Inc. offers a rare-disease pipeline built for clear unmet need: KER-050 targets anemia and thrombocytopenia in myelodysplastic syndromes and myelofibrosis, while KER-012 addresses severe bone fragility in osteoporosis and osteogenesis imperfecta. Its value lies in first-in-class biology, few approved alternatives, and multiple shots at value creation across 3 clinical assets.
| Asset | Need |
|---|---|
| KER-050 | Cytopenias |
| KER-012 | Bone fragility |
Customer Relationships
Investigator-led trial support
Keros Therapeutics, Inc. relies on trial investigators and site staff to recruit patients and keep dosing and visit schedules on protocol. In rare-disease studies, where each enrolled patient can move timelines, strong site support can shorten start-up and speed readout by weeks.
That makes investigator-led support a direct execution lever: better training, faster query resolution, and steady site contact help protect data quality and enrollment momentum.
Key opinion leader engagement
Keros Therapeutics relies on key opinion leaders, mainly specialist physicians, to shape trials in MDS, myelofibrosis, bone disease, and PAH; their input helps refine endpoints and patient selection. In 2025, the Company advanced its pipeline with multiple mid-stage studies, so these experts also help drive later medical adoption across hematology and pulmonology.
Patient recruitment and retention support
Keros Therapeutics, Inc. must actively screen, follow up, and retain eligible patients because rare-disease trials often enroll small cohorts and every visit matters. In its FY2025 reporting, Keros still had no product revenue, so trial execution and patient retention remain core to moving programs forward.
Scientific communication
Keros Therapeutics uses scientific communication to build trust through data readouts, congress talks, and publications, so physicians and investors can judge the programs on evidence, not hype. This transparency supports trial awareness and helps the market follow readout timing, safety signals, and patient response trends.
- Builds trust with data-first updates
- Educates physicians and investors
- Raises awareness for trials
Regulatory and medical dialogue
Keros Therapeutics, Inc. keeps a formal, continuous dialogue with regulators and medical experts, because safety, efficacy, and endpoint choices can change study design fast. In 2025, that kind of oversight matters even more for a biotech with only a small set of clinical assets, where one protocol call can steer the whole pipeline.
- Ongoing FDA and expert input
- Safety and efficacy drive choices
- Endpoint talks shape trial design
Keros Therapeutics Relies on Trial Relationships as Revenue Remains $0
Keros Therapeutics, Inc. keeps customer ties centered on trial investigators, site staff, patients, regulators, and key opinion leaders. In FY2025, the Company still had no product revenue, so these relationships directly support enrollment, data quality, and readouts.
Its best customer work is steady site support, expert input on endpoints, and clear scientific updates that help physicians and investors track safety and efficacy.
| FY2025 metric | Value |
|---|---|
| Product revenue | $0 |
Channels
Clinical trial sites
Patients enter Keros studies through specialist trial sites, which serve as the main channel for all 3 clinical-stage assets and generate the patient-level safety and efficacy data that drive readouts. For a development-stage company, this site network is the core execution layer, with enrollment speed and data quality shaping each trial milestone.
Investigator networks
Keros Therapeutics, Inc. relies on investigator networks built around hematology and bone-disease experts to speed site activation and keep referral flow steady in rare diseases. These specialist links matter because Keros is running late-stage clinical work in hard-to-find patient groups, where each qualified site can drive faster enrollment and cleaner data.
Scientific congresses
Scientific congresses are a key channel for Keros Therapeutics, Inc. to disclose clinical data, reaching physicians, researchers, and potential partners at meetings such as ASH and other specialty events. These forums build pipeline awareness fast, which matters for a development-stage company that reported no product revenue in 2025 and still depends on data readouts to drive interest.
Peer-reviewed publications
Peer-reviewed publications let Keros Therapeutics, Inc. turn trial readouts and mechanism data into citable evidence, which matters in hard-to-treat diseases where trust drives adoption. They also help educate clinicians and payors; Keros said it had $552.6 million in cash, cash equivalents and marketable securities at 2024 year-end, giving it room to keep publishing and de-risking the story.
- Show trial and mechanism data.
- Build credibility in rare diseases.
- Help educate the market.
Corporate and investor communications
Keros Therapeutics, Inc. uses web updates, SEC filings, and earnings materials to reach shareholders and analysts. As a clinical-stage public company, it must keep capital-markets access open through regular 10-Q, 10-K, and earnings disclosure, which investors use to track cash runway, trial progress, and dilution risk.
- SEC filings support legal disclosure
- Earnings materials guide investor views
- Web updates keep the market current
Keros’ Rare-Disease Channel Strategy: Trials First, Data Next
Keros Therapeutics, Inc. reaches patients mainly through specialist trial sites and investigator networks, since its channels are built around rare-disease enrollment, data capture, and late-stage readouts. Congresses, publications, and SEC/web updates then push those results to doctors, partners, and investors; the Company reported no product revenue in 2025.
| Channel | Use |
|---|---|
| Trial sites | Enroll patients |
| ASH/SEC/web | Share data |
Customer Segments
MDS patients with cytopenias
MDS patients with cytopenias are a core target for KER-050, especially those with anemia and thrombocytopenia. In myelodysplastic syndromes, anemia affects over 80% of patients and thrombocytopenia is seen in roughly 30% to 50%, while U.S. incidence is about 10,000 to 20,000 new cases a year, so unmet need stays high because current options are limited.
Myelofibrosis patients with cytopenias
KER-050 also targets myelofibrosis patients with cytopenias, a group where blood cell suppression is common and often limits dosing; in real-world care, anemia affects about 60% to 70% of patients and thrombocytopenia about 15% to 35% at diagnosis. The program aims to lift blood counts, which could help patients stay on therapy and reduce transfusion burden.
Anemia patients for KER-047
KER-047 targets anemia patients with low hemoglobin from multiple causes, a large need area: the WHO estimates anemia affects about 1.9 billion people worldwide. The program is still in Phase 1, so Keros Therapeutics, Inc. is testing safety and early efficacy before any broader use.
Osteoporosis and osteogenesis imperfecta patients
Keros Therapeutics, Inc. targets osteoporosis and osteogenesis imperfecta patients with KER-012 in bone degeneration disorders. This is a musculoskeletal segment, not hematological, and the need is clear: osteoporosis affects about 10 million U.S. adults, while osteogenesis imperfecta occurs in roughly 1 in 15,000 to 20,000 births.
- High fracture risk
- Bone-strength loss drives demand
- KER-012 fits musculoskeletal care
Pulmonary arterial hypertension patients
KER-012’s PAH target widens Keros Therapeutics, Inc. beyond bone disease into a rare-cardiopulmonary market. PAH is still a niche segment, with estimated prevalence of 15 to 50 cases per million adults, and treatment is driven by a separate specialist base, mainly pulmonologists and cardiologists.
- Expands beyond bone disease
- Targets rare-disease PAH patients
- Reaches specialist prescribers
Keros Targets Rare Diseases With High-Unmet-Need Patient Groups
Keros Therapeutics, Inc. serves rare-disease patients with severe cytopenias and bone or cardiopulmonary disorders, led by myelodysplastic syndromes, myelofibrosis, anemia, osteoporosis, osteogenesis imperfecta, and pulmonary arterial hypertension. These groups are small but high-need, with U.S. MDS incidence around 10,000 to 20,000 a year and osteoporosis affecting about 10 million U.S. adults.
| Segment | Need |
|---|---|
| MDS, MF | Cytopenias |
| Anemia | Low hemoglobin |
| Bone, PAH | Rare specialist care |
Cost Structure
Clinical trial expenses
Clinical trial expenses are the main cost driver for Keros Therapeutics, Inc.: trial sites, patient visits, data management, and monitoring all scale fast as programs move across more indications. In its latest filings, research and development stayed the largest spend line, which is typical for clinical-stage biotech, where most cash goes to running studies rather than selling products.
Manufacturing and CMC costs
Keros Therapeutics, Inc. bears manufacturing and CMC costs for drug substance and drug product through either internal runs or outsourced CDMO supply, and GMP production raises spend for clinical lots. Quality testing adds another layer of cost, since each batch needs release and stability checks before use.
Research and development payroll
Scientists, clinicians, and development staff drive Keros Therapeutics, Inc.’s 3-asset pipeline, so research and development payroll stays one of the company’s biggest fixed costs. Stock-based pay can add to that burden, since biotech firms often use equity grants to retain scarce talent and preserve cash.
Regulatory and safety operations
Regulatory and safety operations are a fixed clinical-development cost for Keros Therapeutics, Inc. because IND filings, safety reporting, and quality systems need specialist staff, vendors, and legal review; for a clinical-stage Company, these controls are non-optional and usually rise as trial count and patient exposure grow.
They also add compliance overhead through FDA submissions, adverse-event reporting, and audit-ready quality systems, which can pressure R&D spend even before any product revenue is earned.
- IND, safety, and quality work need specialists
- Mandatory in clinical development
- Drives legal and compliance expense
General and administrative overhead
Keros Therapeutics, Inc. general and administrative overhead covers headquarters, finance, legal, and investor relations, plus Lexington facility and corporate costs. IP maintenance is also part of this fixed base, so overhead stays tied to scale and patent activity more than product sales.
- HQ and support staff
- Lexington site costs
- IP upkeep and legal spend
Keros’ 2025 Burn Is Driven by Trials, CMC, and Overhead
Keros Therapeutics, Inc. is cost-heavy in 2025: R&D stayed the main drain, led by trial execution, CDMO manufacturing, and clinical payroll, while G&A covered HQ, legal, IR, and IP upkeep. These are fixed or semi-fixed costs, so spend rises fast as programs and patient counts grow.
| Cost line | 2025 driver |
|---|---|
| R&D | Trials, CMC, staff |
| G&A | HQ, legal, IP |
Revenue Streams
No commercial product sales yet
Keros Therapeutics, Inc. is still a clinical-stage Company, and it has no approved therapies in its pipeline, so it has no marketed-product revenue. In 2025, its revenue remained $0, with cash used in operations driven by R&D rather than sales.
Future KER-050 sales
KER-050 has no product revenue yet, but if approved it could become Keros Therapeutics, Inc.’s biggest long-term sales stream. The lead markets are myelodysplastic syndromes and myelofibrosis, two blood cancers with clear unmet need and room for premium specialty pricing.
In 2025, Keros Therapeutics, Inc. still had no commercial KER-050 sales, so this is a pure pipeline bet. That makes approval timing and label breadth the main revenue drivers.
Future KER-047 sales
Keros Therapeutics, Inc. had no product sales in 2025, so KER-047 could add a new revenue stream if late-stage data and approval follow.
Because KER-047 targets anemia and is a small-molecule candidate, it could support broader commercialization and reduce reliance on one future source of income.
Future KER-012 sales
KER-012 is a pre-commercial pipeline asset, so its revenue would come only after approval, but it could open two specialist markets: bone disease and pulmonary arterial hypertension (PAH). PAH affects about 48 to 55 people per million in the U.S., and osteoporosis affects about 200 million people worldwide, which would spread future sales across more than one indication.
- Bone disease adds a second revenue lane.
- PAH reaches a rare-disease specialist market.
- Two uses reduce sales concentration risk.
Licensing, milestones, and royalties
Keros Therapeutics, Inc. can use licensing deals to collect upfront cash, then add development milestones and future royalties if a partner advances a program. For a clinical-stage biotech with no approved products, this kind of non-dilutive income can help fund trials before launch and reduce reliance on new stock sales.
- Upfront fees fund near-term R&D
- Milestones pay on progress
- Royalties can scale after launch
- No product sales yet means upside matters
Keros Has No Sales Yet—Pipeline and Licensing Are the Revenue Story
Keros Therapeutics, Inc. had no product revenue in 2025, so revenue streams still depend on approvals, licensing, and future royalties. The main upside is KER-050, with KER-047 and KER-012 as added pipeline bets; any cash today would likely come from upfront fees and milestones, not sales.
| Source | 2025 | Revenue type |
|---|---|---|
| Products | 0 | No sales |
| Licensing | Possible | Upfront, milestones, royalties |
| Pipeline | Pre-launch | Future sales only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.